close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sana Biotechnology, Inc. - Common Stock (NQ:SANA)

3.505 +0.105 (+3.09%)
Streaming Delayed Price Updated: 12:40 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sana Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at June 2026 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Peraso (NASDAQ: PRSO) Delivers Military Drone IFF Systems, Stock Sets Up for Potential Re-Coil
Via AB Newswire
News headline image
Reloading Alert: PRSO, SANA, ROLR, PMNT – Catalysts Align as Momentum Builds
Via AB Newswire
Topics Artificial Intelligence Derivatives
News headline image
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at March 2026 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at December 2025 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at September 2025 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Pricing of Public Offering
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes 
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at June 2025 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.